Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Exocrine Pancreatic Insufficiency Treatment Market Size

The exocrine pancreatic insufficiency treatment market was valued at USD 4.22 billion in 2023, driven by the increasing cases of cystic fibrosis, which commonly develop EPI due to thickened secretions that obstruct the pancreatic ducts across the 8 major markets. The market is expected to grow at a CAGR of 8.27% during the forecast period of 2024-2032, with the values likely to reach USD 8.63 billion by 2032.

Global Exocrine Pancreatic Insufficiency Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Exocrine Pancreatic Insufficiency Treatment Market Outlook

  • The incidence of chronic pancreatitis, a leading cause of EPI, is rising due to factors such as alcohol abuse, smoking, and obesity, which is driving the growth of the market. According to an article pu blished by National Institute of Health, the annual incidence of acute pancreatitis (AP) is estimated to be approximately 40/100,000 persons in the United States, resulting in over 130,000 new cases per year.
  • Increasing incidence of pancreatic cancer, often associated with EPI due to tumor-induced obstruction of pancreatic ducts is expected to further fuel the market growth.
  • The ongoing research into new therapeutic targets and formulations for exocrine pancreatic insufficiency treatment drives market expansion. Companies are leveraging technological advancements in biotechnology and drug delivery systems to enhance product offerings results into market expansion.

Exocrine Pancreatic Insufficiency Treatment Market Overview

Exocrine pancreatic insufficiency (EPI) is a condition characterized by the inability of the pancreas to produce enough digestive enzymes to properly digest food. The treatment includes PERT, which involves taking pancreatic enzyme supplements with meals and snacks to replace the deficient enzymes. The enzyme supplements typically contain lipase, protease, and amylase to aid in the digestion of fats, proteins, and carbohydrates.

EPI is primarily caused by conditions that affect pancreatic function, such as chronic pancreatitis, cystic fibrosis, pancreatic cancer, and pancreatic surgery. The prevalence of these underlying conditions contributes to the growing demand for EPI treatment market.

The pharmaceutical companies are focusing on developing advanced formulations of pancreatic enzymes to improve stability, efficacy, and patient compliance. These innovations aim to optimize treatment outcomes and enhance patient satisfaction, which is expected to drive the market growth.

Exocrine Pancreatic Insufficiency Treatment Market Growth Drivers

Increasing Incidence and Prevalence of Underlying Conditions

Chronic pancreatitis is a significant cause of EPI, which is increasingly diagnosed due to rising cases linked to alcohol abuse, obesity, and other factors. This genetic condition affects pancreatic function, leading to EPI in a substantial number of patients. According to an article published by NCB I, chronic pancreatitis is the most common pancreatic disease associated with EPI.

Other conditions like pancreatic cancer and surgical interventions on the pancreas can impair its ability to produce digestive enzymes, necessitating EPI treatment. According to an article published by NCB I, pancreatic surgery alters digestive anatomy, the correct mixing of food, bile, and pancreatic enzymes and reduces the pancreatic volume. Different procedures are associated with different degrees of EPI. The growing number of individuals diagnosed with chronic pancreatitis directly expands the pool of patients at risk of developing EPI, thereby increasing the demand for its treatment market.

Technological Advancements in Treatment Options is Expected to Propel Exocrine Pancreatic Insufficiency Treatment Market Demand

The technological advancements in treatment options play a crucial role in driving the growth and development of the treatment market. The technological innovations enable the development of more effective formulations of pancreatic enzymes, including lipase, protease, and amylase. These formulations are designed to better mimic natural pancreatic enzyme activity, thereby improving digestion and nutrient absorption in patients with EPI. Pancreatic Enzyme Replacement Therapy (PERT) remains the mainstay of EPI treatment, with ongoing advancements in enzyme formulations, delivery systems, and dosing regimens to enhance efficacy and patient compliance.

The advancement in treatment includes other alternative therapies, exploration of adjunctive therapies, such as proton pump inhibitors (PPIs), dietary modifications, and nutritional supplements, provides additional treatment options tailored to patient needs. This innovation leads to increase in market demand.

Global Exocrine Pancreatic Insufficiency Treatment Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Exocrine Pancreatic Insufficiency Treatment Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Key Trends Impact
Advancements in Enzyme Replacement Therapy There is ongoing research and development aimed at enhancing the efficacy, stability, and bioavailability of pancreatic enzyme replacement therapy (PERT). The innovations include formulations with optimized enzyme ratios, enteric-coated tablets for improved delivery, and microencapsulation technologies to protect enzymes from degradation. These advancements are expected to drive the market growth.
Exploration of Novel Therapies The ongoing research efforts are focused on exploring novel therapeutic approaches beyond traditional enzyme replacement, including enzyme enhancers, pancreatic duct clearance agents, and targeted therapies addressing underlying disease mechanisms.
Personalized Medicine Approach The increasing use of genetic testing helps identify specific mutations (e.g., CFTR mutations in cystic fibrosis-related EPI) that influence treatment responses. This allows for personalized treatment plans tailored to individual genetic profiles, optimizing therapy effectiveness and patient outcomes. This is expected to drive market growth.

Exocrine Pancreatic Insufficiency Treatment Market Segmentation

Market Breakup by Treatment

  • Pancreatic Enzyme Replacement Therapy (PERT)
  • Nutritional Therapy (Dietary Supplements)
  • Others

Market Breakup by Indication

  • Abdominal Pain
  • Constipation
  • Diarrhea
  • Fatty Stools
  • Weight Loss
  • Others

Market Breakup by End User

  • Hospitals
  • Homecare
  • Specialty Centers
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

Exocrine Pancreatic Insufficiency Treatment Market Share

Market Segmentation Based on Treatment is Anticipated to Witness Substantial Growth

By treatment, the market is segmented into pancreatic enzyme replacement therapy (PERT), nutritional therapy (dietary supplements) and others. The pancreatic enzyme replacement therapy (PERT) segment is expected to dominate the market because it is the most recommended treatment. It helps in managing EPI symptoms by replacing the deficient pancreatic enzymes (lipase, protease, amylase) required for proper digestion of fats, proteins, and carbohydrates.

Global Exocrine Pancreatic Insufficiency Treatment Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Exocrine Pancreatic Insufficiency Treatment Market Analysis by Region

Regionally, the market report offers an insight into the United States, EU-4 and the United Kingdom, Germany, France, Italy, Spain, United Kingdom, Japan, and India. The United States, having a robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies, is estimated to hold a high market value. The robust research and development activities in pharmaceutical and biotechnology sectors, leading to continuous advancements in pancreatic enzyme replacement therapy (PERT) formulations, driving the regional demand.

Germany holds a high exocrine pancreatic insufficiency treatment market value as the region boasts a well-developed healthcare system with robust diagnostic capabilities and access to specialized care, facilitating early detection and management of EPI.

Additionally, Japan is expected to witness substantial market growth as the region has made significant progress in raising awareness among healthcare providers about gastrointestinal disorders, including EPI. This has led to improved diagnosis and management of the condition and thus driving the market demand.

Leading Players in the Exocrine Pancreatic Insufficiency Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, fundings and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AbbVie Inc.

AbbVie Inc., a prominent pharmaceutical company, has been involved in the treatment of exocrine pancreatic insufficiency (EPI) through its development and marketing of pancreatic enzyme replacement therapy (PERT) products.

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc., as a global pharmaceutical company focuses on several therapeutic areas such as pharmaceuticals, generics, eye care, and oncology, among others, including EPI.

Other key players in the market include Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc., Cilian AG, Chiesi Farmaceutici S.p.A., Anthera Pharmaceuticals, Inc., and Aptalis Pharma Inc. among others.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Treatment
  • Indication
  • End User
  • Region
Breakup by Treatment
  • Pancreatic Enzyme Replacement Therapy (PERT)
  • Nutritional Therapy (Dietary Supplements)
  • Others 
Breakup by Indication
  • Abdominal Pain
  • Constipation
  • Diarrhea
  • Fatty Stools
  • Weight Loss
  • Others 
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Centers
  • Others 
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India 
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AbbVie Inc.
  • Johnson & Johnson Services, Inc. 
  • Chiesi Farmaceutici S.p.A. 
  • Nordmark Arzneimittel GmbH and Co. KG 
  • Digestive Care, Inc. 
  • Cilian AG  
  • Anthera Pharmaceuticals, Inc.
  • Aptalis Pharma Inc.

Key Questions Answered in the Exocrine Pancreatic Insufficiency Treatment Market Report

  • What was the exocrine pancreatic insufficiency treatment market value in 2023?
  • What is the exocrine pancreatic insufficiency treatment market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on treatment?
  • What is market segmentation based on indication?
  • What is market segmentation based on end user?
  • What are the major factors aiding the exocrine pancreatic insufficiency treatment market demand? 
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major trends influencing the market? 
  • What are the market's major drivers, opportunities, and restraints? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • How does the growing cases of chronic pancreatis affect the market landscape?
  • How does the clinical trials impact the market size?
  • Who are the key players involved in the exocrine pancreatic insufficiency treatment market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124